Pharmaceuticals, Free Full-Text

$ 8.50 · 4.6 (778) · In stock

Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of small molecule drugs do not cross the BBB, and ~100% of biologic drugs do not cross the BBB, so BBB drug delivery technology is needed in AD drug development. Second, the pharmaceutical industry has not developed BBB drug delivery technology, which would enable industry to invent new therapeutics for AD that actually penetrate into brain parenchyma from blood. In 2020, less than 1% of all AD drug development projects use a BBB drug delivery technology. The pathogenesis of AD involves chronic neuro-inflammation, the progressive deposition of insoluble amyloid-beta or tau aggregates, and neural degeneration. New drugs that both attack these multiple sites in AD, and that have been coupled with BBB drug delivery technology, can lead to new and effective treatments of this serious disorder.

Animal Pharmaceuticals

Bleeding disorders linked to synthetic cannabinoids use- State

Photoelectrocatalytic degradation of pharmaceuticals promoted by a metal- free g‑C3N4 catalyst - ScienceDirect

PDF) Pharmaceuticals, intellectual property and free trade: the case of the US-Australia Free Trade Agreement

Pharmaceuticals, Free Full-Text

HFZA concludes successful participation in International Conference of Pharmacy & Medicine - Hamriyah Free Zone Authority

Nitrosamine-Free Pharmaceuticals

Pharmaceutical Chemist Job Description Template - Edit Online & Download Example

Pharmaceuticals, Free Full-Text

Assessment of Soil Moisture Uptake under Different Salinity Levels for Paddy Crop, Journal of Irrigation and Drainage Engineering

Pharmacology Cheat Sheet: Generic Drug Stems - Nurseslabs